Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension

NCT04474899 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Obesity
Hypertension

Interventions

DRUG: Moxonidine 0.4 MG
DRUG: Amlodipine 5mg

Sponsor

Royal Perth Hospital

Collaborators

[object Object]